Skip to main content
OpenTrials
Completed

NCT Number: NCT05858138

To Explore the Effectiveness of Jing-Si Herbal Tea Against Non-alcoholic Fatty Liver Disease

The aim of this study is to explore the effectiveness of Jing-Si Herbal Tea on improving the Non-alcoholic fatty liver disease patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-Alcoholic Fatty Liver Disease Digestive System Diseases Fatty Liver Liver Diseases

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Taichung Tzu Chi Hospital

Taichung, Taiwan, 42743

About this study

This study adopted a randomized double-blind design, 2-arm trial study. All eligible patients included in the study agreed to participated and signed the informed consent from and the study procedures were approved by the ethical committee of Taichung Tzu Chi general hospital (REC110-74). Patients were recruited from the Gastroenterology department of Taichung Tzu Chi hospital. After random assignment to 2 groups, patients will receive Jing-Si Herbal Tea or placebo twice a day for 24 weeks. We will evaluate the blood test results, abdominal ultrasound and physical examination every 12 weeks.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sign the Informed consent
  • Age between 20-70
  • Diagnosis for moderated NAFLD
  • Liver disease without hepatic decompensation
  • HbA1c < = 8.0 %

Exclusion criteria

  • Do not sign the Informed consent
  • Other related liver diseases will affect the study which evaluated by physicians
  • Women of potential pregnancy or pregnant women

Treatment and study plan

Jing-Si Herbal Tea

Other

patient will receive twice in a day for 24 weeks

Placebo Jing-Si Herbal Tea

Other

Placebo Jing-Si Herbal Tea

Primary outcomes

  1. Assessing the changes from baseline blood glucose at 24 week

    Time frame: 24 week

    Collect the data of blood glucose from blood test

  2. Assessing the changes from baseline GOT (Glutamic Oxaloacetic Transaminase) at 24 week

    Time frame: 24 week

    Collect the data of GOT from blood test

  3. Assessing the changes from baseline GPT (Glutamic Pyruvic Transaminase) at 24 week

    Time frame: 24 week

    Collect the data of GPT from blood test

  4. Assessing the changes from baseline total cholesterol at 24 week

    Time frame: 24 week

    Collect the data of total cholesterol from blood test

  5. Assessing the changes from baseline triglycerides at 24 week

    Time frame: 24 week

    Collect the data of triglycerides from blood test

  6. Assessing the changes from baseline HDL-C at 24 week

    Time frame: 24 week

    Collect the data of HDL-C from blood test

  7. Assessing the changes from baseline LDL-C at 24 week

    Time frame: 24 weekk

    Collect the data of LDL-C from blood test

  8. Assessing the changes from baseline NAFLD activity at 24 week

    Time frame: 24 week

    Scoring the level of NAFLD activity

  9. Assessing the changes from baseline BMI at 24 week

    Time frame: 24 week

    Collect the body height and body weight, weight and height will be combined to report BMI in kg/m^2

Sponsors and collaborators

Lead sponsor

Taichung Tzu Chi Hospital

Other

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
May 15, 2023
Registry last updated
Sep 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.